Kimiko Domoto-Reilly, MD Cognitive / Behavioral Neurology Fellow Massachusetts General Hospital & Brigham and Women’s Hospital.

Slides:

Advertisements

Similar presentations

December, NEED FOR VALIDATED BIOMARKERS FOR AD TRIALS Biomarkers useful in Phase 2 to make decisions about Phase 3 (e.g. doses) Biomarkers useful.

Advertisements

DIAN Treatment Trials An Update Sunday February 10, :00 to 6:00 PM CST Presented by Randall Bateman MD DIAN Therapeutic Trials Unit Director DIAN.

Frontotemporal Dementia

PRoBaND Parkinson’s Repository of Biosamples and Networked Datasets History Hypotheses Overview Linkage to other studies Funded by Parkinson’s UK Dr Donald.

Clinical trials with DeNDRoN in the North East Dr Margaret Piggott Data and Communications Manager Dementias and Neurodegenerative.

Estate Planning and the Neuropsychologist

Medical College of Wisconsin Functional Imaging Research Center Stephen M. Rao, Ph.D., Director Professor of Neurology

Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE April

Caregiver Concerns and Support in FTD Aly Negreira, BA MGH Frontotemporal Disorders Unit.

University of Kansas Medical Center

ACT on Alzheimer’s Disease Curriculum Module VII: Disease Diagnosis.

A 67-year-old male with behavioral and language problems

Kimiko Domoto-Reilly, MD 1,2,5 Daisy Sapolsky, MS, CCC-SLP 1,3,4 Aly Negreira, BA 1,3 1 Frontotemporal Disorders Unit, Departments of 2 Neurology, 3 Psychiatry,

Alzheimer’s Assessment Assessing the Cognitive-Linguistic effects of Alzheimer’s.

FTD Family Members Study & Post Mortem Study Alyson Negreira MGH Frontotemporal Disorders Unit.

ALZHEIMER’S DISEASE BY OLUFOLAKUNMI KEHINDE PRE-MD 1.

©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar.

Update Arg-ADNI Gustavo E. Sevlever, Ricardo F. Allegri (*), Silvia Vázquez, Deborah R. Gustafson, Salvador M. Guinjoan, and Arg-ADNI group. Memory and.

Parkinson’s Plus By: Glen Estrosos.

Alzheimer’s Disease The most common cause of Dementia –Progressive Memory Loss Plus loss in one other area of cognition: Perception Attention Language/Symbols.

Jack Twersky, MD Medical Director CLC Durham.  Memory impairment and at least one of the following  Aphasia  Apraxia  Agnosia  Executive function.

By OPAL & Memory Team Improving the Individual Experience – Getting the System Right EARLY DIAGNOSIS INTEGRATED CARE PATHWAY RBCH Model.

Laurence Lacoste Ph. D, Paris, France 1*. Introduction : Why ?  Population’s Ageing is a Public Health issue and dementia for the Elderly a reality 

Alzheimer’s Disease  Goals  To understand what dementia is  To explore causes, risk factors, symptoms, and treatments of Alzheimer’s Disease  To better.

Disclosure of research results: should policies be changed? Melanie B. Shulman, M.D., M.Phil. Clinical Associate Professor of Neurology and Psychiatry.

How to diagnose dementia? Dr. Sridhar Vaitheswaran 25 th October 2012.

Are spatial tasks useful for the early diagnosis of Alzheimer’s disease.

Adverse Outcomes After Hospitalization and Delirium in Persons with Alzheimer Disease Charles Wang, PharmD Candidate.

Non Alzheimer's Dementias Elizabeth Landsverk, MD Geriatrician, ElderConsult Geriatric Medicine Adjunct Professor of Medicine, Stanford University.

Focal Syndromes Dr Stephen Pearson Consultant in Old Age Psychiatry Devon Partnership Trust.

GERIATRIC EDUCATION SERIES Presented in partnership by Funded in part by a grant from the EJC Foundation.

Dementia: Alzheimer’s Disease Cyril Evbuomwan Patient Group Meeting 1 st December 2015.

Neurobiology of Dementia Majid Barekatain, M.D., Associate Professor of Psychiatry Neuropsychiatrist Isfahan University of Medical Sciences Ordibehesht.

Update and Thank you to participants Bradley Hyman MD PhD Director, Mass ADRC ViceChair, Neurology, Massachusetts General Hospital.

Brigham and Women’s Hospital GCRC – BIRN Collaboration Planning August Two active GCRC protocols were selected to be part of the initial collaboration.

Structural and Functional Neuroimaging in the Diagnosis of Dementia John M. Ringman, M.D. Assistant Professor UCLA Department of Neurology.

Biomarkers of Alzheimer’s Disease. Objectively mark Presence of neurodegenerative pathology Change in pathologic activity Purpose.

1 Cognitive Impairment and Dementia: What You Need to Know about Alzheimer's Disease and Related Disorders Part 2 – Clinical focus Susan Rowlett, LICSW.

Types of Dementia Dr Bernie Coope Associate Medical Director/Honorary Senior Lecturer, Worcester University Association for Dementia Studies.

CASES SERIES BRAIN FDG PET SCAN IN DEMENTIA PATIENTS

AFTD Education Conference Research Update: Focus on Two Large Federally Funded Projects: LEFFTDS and ARTFL David Knopman MD Neurology Mayo Clinic Rochester.

Frontotemporal Lobar Degeneration:

Dementia F.Etessam. MD. Dementia A progressive impairment of cognitive functions occurring in clear consciousness.

DEMENTIA 1/6/16 DR TONY O’BRIEN MD FRCP. Dementia Common – 700,000 sufferers in the UK Common – 700,000 sufferers in the UK Prevalence increases with.

Dementia Jaqueline Raetz, M.D.. Types of Dementia Alzheimer Dementia 70% Lewy Body Dementia about 22% Vascular Dementia 17% Frontotemporal Dementia Overall.

Laura Baker, PhD Internal Medicine, Neurology, & Public Health Sciences Wake Forest School of Medicine Winston-Salem, NC USA.

Arg-ADNI Patients’ Flowchart Patients Invited to ADNI Nº= 73

Clinical Neuropsychology

Presenter: Dr. Patricio Chrem

By: Johanna Miner, Kendra Hobbs and Ainsley MAcDonald

Use of Amyloid PET Scan in Early Diagnosis of Alzheimer’s Disease in a Secondary Care Memory Clinic Niki Schoonenboom, MD PhD1, Mohammed Akarriou, MD2;

90 Year Olds are Less Likely to Fall if they were Physically Active Two Decades Earlier: The 90+ Study Dana Greenia RN MS1, Annlia Paganini-Hill PhD2,

Frontotemporal dementia syndromes are united by underlying frontotemporal lobar degeneration pathology, which can be divided according to the presence.

Fig. 11. Algorithm for differential diagnosis of cognitive impaired subjects by employing structural imaging. AD = Alzheimer's disease, BG = basal ganglia,

A 66 year-old woman with progressive speech difficulty

Image Challenge Q: A 70-year-old woman presented to the neurology clinic with a 2-year history of gait disturbance, cognitive impairment, and urinary incontinence.

Table 2. Data Sharing for (Reporting Period)

Imaging AD Progression Amyloid Imaging Agents.

Cognitive Disorders and Aging

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Cerebrospinal fluid levels of neurofilament light chain

Mark S. Forman, Virginia M-Y. Lee, John Q. Trojanowski Neuron

Presenter: Dr. Patricio Chrem

Chapter 93 Dementias and Related Disorders

Updated: 29/11/2018 Number of responses: 22

Argentina Arg-ADNI Ezequiel Surace, PhD.

A Drug Trial as Experienced by a Person with Dementia

NEUROIMAGING FINDINGS OF RARE NEURODEGENERATIVE DISEASES RELATED TO DEMENTIA SYMPTOMS INTRODUCTION: Neurodegenerative diseases are diversified group of.

Postmortem Neurological Diagnosis A Postmortem Neurological Diagnosis or Brain-Only Autopsy, is the only definitive answer for families or researchers.

Impact of approaches for clinical and radiological monitoring on predicting of short-term and long-term disability outcomes in multiple sclerosis Brian.

Presentation transcript:

Kimiko Domoto-Reilly, MD Cognitive / Behavioral Neurology Fellow Massachusetts General Hospital & Brigham and Women’s Hospital

Background: ADNI  Alzheimer’s Disease Neuroimaging Initiative (2004)  natural history study of early Alzheimer’s disease  800 subjects from 50 sites across North America  control subjects and subjects with memory impairment  6-12 month evaluations over 3 years  clinical / cognitive assessments  brain scans: MRI, PET  biofluid collection: blood, urine, CSF  funded by National Institute on Aging, the Alzheimer’s Association, and multiple drug companies

Background: ADNI  freely shared data repository  many new insights into Alzheimer’s disease  European-ADNI (2006); Japanese-ADNI (2006); ADNI-GO (2010); ADNI II (2011); Parkinson’s Progression Markers Initiative

NIFD: Overview  Neuroimaging in Frontotemporal Dementia  natural history study of early FTD  215 subjects from 3 sites (UCSF, Mayo, MGH)  140 FTD subjects, 75 control subjects  here at MGH: 25 FTD subjects  6 month evaluations over 1.5 years  clinical / cognitive assessments  brain scans: MRI (and PET at other sites)  biofluid collection: blood, urine, CSF

NIFD: Enrollment  eligibility  diagnosis of bvFTD, PNFA, or SD  fluent in English  years old  study partner  able to undergo multiple MRIs and 2 LPs

NIFD: Schedule Month clinical & cognitive assessments XXXX informant questionnaires XXXX MRIXXXX CSF, blood, urineXX

NIFD: Goals  goals  to collect multimodal data (cognitive/behavioral, imaging, biofluids) in a standardized fashion  to contribute to a shared database  to learn more about the natural history of FTD  to learn more about new imaging techniques and biofluid measurements  to learn about which information is best for diagnosis, prognosis, and monitoring  data collection funded by National Institute on Aging / National Institute of Neurological Disorders and Stroke (NIA-NINDS)

4RTNI: 2012?  4R-Tau Neuroimaging Initiative  design parallels ADNI and NIFD  natural history study  imaging and biofluid collection  Tau-based diseases  corticobasal degeneration (CBD)  progressive supranuclear palsy (PSP)  study funded by an anonymous grant from a family of a patient cared for at UCSF